What the changes say
- Rezolute is focusing on commercial readiness, adding growth and market capitalization risks as it scales past a $678.4M valuation.
- The company updated macroeconomic and tax risk factors to explicitly incorporate tariffs, trade policy, and federal tax changes.
What changed since the prior 10-K
New
- NewRisks Related to Our Product Development and Commercialization
We may be unable to manage our anticipated growth effectively
Moving our product candidates toward commercialization will strain our 77 employees, operational systems, and internal controls, requiring extensive hiring across multiple departments.
- NewRisks Related to Our Product Development and Commercialization
Further, our anticipated growth will place additional strain on our suppliers, resulting in an increased need for us to carefully monitor quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals
Our anticipated growth will strain suppliers and risk management structures, threatening our transition from a development-stage company to a commercial operation.
- NewRisks Related to Our Business
In the future we may not qualify as are no a “smaller reporting company” within the meaning of the Securities Act and as a result we would be will be subject to certain enhanced disclosure requirements which will require us to incur significant expenses and expend time and resources
Our $678.4 million market capitalization may cause us to lose smaller reporting company status, triggering costly Sarbanes-Oxley audit and executive compensation disclosure requirements.
- NewRisks Related to Our Common Stock
One Big Beautiful Bill Act (“OBBBA”)
The enactment of the One Big Beautiful Bill Act creates uncertainty and potential adverse effects that we are currently assessing.
Dropped
- DroppedRisks Related to Our Product Development and Commercialization
We are exposed to additional risks as we conduct the sunRIZE study outside of the U.S. and may not be successful in meeting the study’s primary endpoint
- DroppedRisks Related to Our Product Development and Commercialization
candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply of such product candidates, which would impair our ability to generate revenues from the sale of our product candidates
- DroppedRisks Related to Our Product Development and Commercialization
Guidelines and recommendations published by various organizations may adversely affect the use of any products for which we may receive regulatory approval
Risks related to conducting the sunRIZE study outside the U.S.
- DroppedRisks Related to Our Business
Changes in financial accounting standards or policies have affected, and in the future may affect, our reported financial condition or results of operations; there are inherent limitations to our system of internal controls; changes in corporate governance policies and practices may impact our business
- DroppedRisks Related to Our Common Stock
Exercise or conversion of warrants, stock options and other convertible securities will dilute shareholder’s percentage of ownership
- DroppedRisks Related to Our Common Stock
Our stock price may be volatile
- DroppedRisks Related to Our Common Stock
We have no current plan to pay dividends on our common stock and investors may lose the entire amount of their investment
Reworded
- 85% rewrittenRisks Related to Our Business
Unfavorable global and regional economic and political conditions could adversely affect our business, financial condition or results of operations
Added specific mentions of tariffs and retaliatory U.S. trade policies impacting the global economy and potentially our business.
Was: Unfavorable global and regional economic, political and health conditions could adversely affect our business, financial condition or results of operations
- 56% rewrittenRisks Related to Our Common Stock
Changes in U.S. tax law could adversely affect our business
Removed specific references to Internal Revenue Code Section 174 capitalization rules for research and development costs.
- 52% rewrittenRisks Related to Our Business
We may not be able to use a significant portion of our net operating loss carryforwards, which could adversely affect our profitability
Updated U.S. federal NOL carryforwards figure from $171.7 million to $201.4 million as of June 30, 2025.
- 36% rewrittenRisks Related to Our Product Development and Commercialization
Any failure or delay by our third-party suppliers on which we rely or intend to rely to provide materials necessary to develop and manufacture our drug products may delay or impair our ability to commercialize our product candidates
Added inflation, tariffs, and global conflicts as specific external forces that could disrupt raw material supplies.
All 28 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Product Development and Commercialization
- 01Any delays in the commencement or completion, or termination or suspension, of our future clinical trials, if any, could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects
- 02Adverse events in our clinical trials may force us to stop development of our product candidates or prevent regulatory approval of our product candidates
- 03After the completion of our clinical studies, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict the timing of any future revenue from these product candidates
- 04If our product candidates do not meet safety or efficacy requirements, they will not receive regulatory approval and we will be unable to market them
- 05Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from ever generating meaningful revenues or achieving profitability
- 06Due to our reliance on contract research organizations or other third parties to conduct clinical trials, we may not have complete control over the timing, conduct and expense of our clinical trials
- 07Any failure or delay by our third-party suppliers on which we rely or intend to rely to provide materials necessary to develop and manufacture our drug products may delay or impair our ability to commercialize our product candidates36% rewritten
- 08We may be unable to manage our anticipated growth effectivelyNew
- 09Further, our anticipated growth will place additional strain on our suppliers, resulting in an increased need for us to carefully monitor quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goalsNew
- 10If we use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages
Risks Related to Our Business
- 11We face potential product liability exposure, and, if successful claims are brought against us, we may incur substantial liability
- 12We may not be able to use a significant portion of our net operating loss carryforwards, which could adversely affect our profitability52% rewritten
- 13If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline
- 14In the future we may not qualify as are no a “smaller reporting company” within the meaning of the Securities Act and as a result we would be will be subject to certain enhanced disclosure requirements which will require us to incur significant expenses and expend time and resourcesNew
- 15Operations outside the United States may be affected by different local politics, business and cultural factors, different regulatory requirements and prohibitions between jurisdictions
- 16Our collection, use, processing, and cross-border transfer of personal information, including individually identifiable health information, is governed by restrictive regulations
- 17We could recognize losses on securities held in our marketable debt securities portfolio, particularly if interest rates increase or economic and market conditions deteriorate
- 18Unfavorable global and regional economic and political conditions could adversely affect our business, financial condition or results of operations85% rewritten
- 19Certain Provisions of Nevada law may have anti-takeover effects
Risks Related to Our Intellectual Property
- 20Our current patent positions and license portfolio may not include all patent rights needed for the full development and commercialization of our product candidates. We cannot be sure that patent rights we may need in the future will be available to license on commercially reasonable terms, or at all
- 21If our or our licensors’ patent positions do not adequately protect our product candidates or any future products, others could compete with us more directly, which would harm our business
- 22We may be unable to adequately prevent disclosure of trade secrets and other proprietary information
- 23Litigation regarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing product candidates to market and harm our ability to operate
- 24If our patent and other intellectual property protection is inadequate, future sales and profits may never materialize or competitors could force our products completely out of the market
Risks Related to Our Common Stock
- 25Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline
- 26Investor relations activities and supply and demand factors may affect the price of our common stock
- 27Changes in U.S. tax law could adversely affect our business56% rewritten
- 28One Big Beautiful Bill Act (“OBBBA”)New
Other Rezolute 10-Ks
- FY2026 10-K risk factors32 risks8 new4 dropped2 reworded
FDA may reject a viable path for ersodetug in congenital HI or require a costly new randomized study after sunRIZE.
Filed Sep 24, 2026 - FY2024 10-K risk factors31 risks
Rezolute faces primary risks around clinical trial execution, regulatory approvals, third-party manufacturing dependencies, and patent protection for its drug candidates.
Filed Sep 19, 2024
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.